This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-08-3701v1 69/8/3579    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Braggio, E. Articles by Fonseca, R. Search for Related Content PubMed PubMed Citation Articles by Braggio, E. Articles by Fonseca, R.

Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-B Signaling Pathways in Waldenström's Macroglobulinemia

¹ Mayo Clinic, Scottsdale, Arizona; ² Dana-Farber Cancer Institute, Boston, Massachusetts; ³ Mayo Clinic, Rochester, Minnesota; and ⁴ Translational Genomics, Phoenix, Arizona

Requests for reprints: Rafael Fonseca, Mayo Clinic Cancer Center, 13400 East Shea Boulevard, Collaborative Research Building, 3-006 Scottsdale, AZ 85259-5494. Phone: 480-301-4280/480-301-8335; Fax: 480-301-8387/480-301-8572; E-mail: fonseca.rafael{at}mayo.edu.

Key Words: Waldenström's macroglobulinemia • aCGH • TRAF3 • TNFAIP3 • NF-B signaling pathways

Waldenström's macroglobulinemia (WM) is a distinct clinicobiological entity defined as a B-cell neoplasm characterized by a lymphoplasmacytic infiltrate in bone marrow (BM) and IgM paraprotein production. Cytogenetic analyses were historically limited by difficulty in obtaining tumor metaphases, and the genetic basis of the disease remains poorly defined. Here, we performed a comprehensive analysis in 42 WM patients by using a high-resolution, array-based comparative genomic hybridization approach to unravel the genetic mechanisms associated with WM pathogenesis. Overall, 83% of cases have chromosomal abnormalities, with a median of three abnormalities per patient. Gain of 6p was the second most common abnormality (17%), and its presence was always concomitant with 6q loss. A minimal deleted region, including MIRN15A and MIRN16-1, was delineated on 13q14 in 10% of patients. Of interest, we reported biallelic deletions and/or inactivating mutations with uniparental disomy in tumor necrosis factor (TNF) receptor–associated factor 3 and TNF-induced protein 3, two negative regulators of the nuclear factor-B (NF-B) signaling pathway. Furthermore, we confirmed the association between TRAF3 inactivation and increased transcriptional activity of NF-B target genes. Mutational activation of the NF-B pathway, which is normally activated by ligand receptor interactions within the BM microenvironment, highlights its biological importance, and suggests a therapeutic role for inhibitors of NF-B pathway activation in the treatment of WM. [Cancer Res 2009;69(8):3579–88]

This article has been cited by other articles:

				K. Honma, S. Tsuzuki, M. Nakagawa, H. Tagawa, S. Nakamura, Y. Morishima, and M. Seto TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas Blood, September 17, 2009; 114(12): 2467 - 2475. [Abstract] [Full Text] [PDF]